LIFE SCIENCES

Marsh's Global Life Sciences Practice's expertise ranges across all segments of the industry. We provide world-class risk services and cutting-edge solutions for organisations in pharmaceutical, drug wholesale, nutraceutical, biotechnology, medical device and supply, and contract research.

Life Sciences

The life sciences industry faces challenging times due to a number of external factors driving change. Our understanding of the special risks facing life sciences companies has made Marsh the leading broker servicing the sector.

  • Litigation and the actions of regulators continue to pose a financial and reputation threat to many companies in the sector.
  • Successful challenges to patents and other forms of intellectual property can quickly undermine a firm’s core product and source of revenue.
  • Meanwhile, the insurance community is increasingly restricting Product Liability insurance cover for life sciences companies.

 We provide risk management services and solutions for companies engaged in pharmaceuticals, biotechnology, medical device manufacturing, healthcare, provision of specialist services such as contract research, analytical laboratories and educational institutions engaged in clinical research.

Marsh has created Centres of Excellence to aggregate our knowledge and expertise of the industry, stay abreast of current economic trends impacting the industry and provide cutting-edge insights and solutions in areas of programme design, placement, service and administration. One such Centre of Excellence exists in the UK.

In partnership with our wider network of Marsh & McLennan Companies, we provide solutions and services such as

  • business risk consulting
  • supply chain management
  • clinical trials risk
  • business continuity planning

We have the right experts and state-of-the-art risk management tools and solutions to help our clients successfully navigate the world of risk.

Change selection(s) to sort. Sort by:
European Commission's plan to revise the Clinical Trials Directive in 2012
May 12, 2011  |  Views: 784 |  Comments: 0 
European Commission's plan to revise the Clinical Trials Directive in 2012
Marsh has provided an update on the process of seeking feedback on proposed changes to the European Commission's Clinical Trials Directive (DIR 2001/20/EC).  Read More...
An explanation of the new directive on clinical trials by the Drugs Controller General of India (DCGI) in India
May 12, 2011  |  Views: 735 |  Comments: 0  | Article Rating
An explanation of the new directive on clinical trials by the Drugs Controller General of India (DCGI) in India
Marsh explains a change in the regulations that apply to clinical trials in India and the responsibilities placed upon Contract Research Organizations (CROs).   Read More...
REACH And Use By Manufacturers of Chemical Substances That Could Be Classified As Carcinogens
April 18, 2012  |  Views: 186 |  Comments: 0  | Article Rating
REACH And Use By Manufacturers of Chemical Substances That Could Be Classified As Carcinogens
Marsh has updated it's September 2010 document "The effect of the restriction of a chemical substance under REACH on product liability policies". The update now includes the latest...  Read More...
Preparing for a Changing Market
January 25, 2012  |  Views: 742 |  Comments: 0 
Preparing for a Changing Market
This publication is a synopsis of presentations made at Marsh's fourth annual Client Conference in London, 6 December 2011.   Read More...
The Foreign Corrupt Practices Act (FCPA) and the UK Bribery Act — How To Safely Conduct International Business Under Increased Scrutiny
July 06, 2011  |  Views: 1228 |  Comments: 0  | Article Rating
The Foreign Corrupt Practices Act (FCPA) and the UK Bribery Act — How To Safely Conduct International Business Under Increased Scrutiny
On Thursday, June 2 Marsh held a one-hour Webcast, "The Foreign Corrupt Practices Act (FCPA) and the UK Bribery Act — How to safely conduct international business under increased s...  Read More...
Webcast Replay - After the Earthquake: Supply Chain Resiliency
May 26, 2011  |  Views: 1618 |  Comments: 0  | Article Rating
Webcast Replay - After the Earthquake: Supply Chain Resiliency
A replay of our New Realilty of Risk Webcast covering supply chain resiliency. The devastating earthquake, tsunami, and nuclear events in Japan were only the latest in a string of ...  Read More...
The UK Bribery Act 2010 - guidance April 2011
May 25, 2011  |  Views: 725 |  Comments: 0 
The UK Bribery Act 2010 - guidance April 2011
For the past year we have been commenting on the new bribery laws passed in the Bribery Act 2010.On 30 March 2011 the Ministry of Justice published long-awaited guidance on the pro...  Read More...
Life and health of patients participating in clinical trials in Russia
May 12, 2011  |  Views: 557 |  Comments: 0 
Life and health of patients participating in clinical trials in Russia
Marsh explains in some detail the substance of the recent changes that have been introduced in Russia for clinical trials.  Read More...
Managing supply chain resiliency in an increasingly risky world
April 25, 2011  |  Views: 1550 |  Comments: 0  | Article Rating
Managing supply chain resiliency in an increasingly risky world
Although it's tempting to categorize the recent earthquake/tsunami/nuclear catastrophe in Japan as a highly improbable "Black Swan" event, the truth is that organizations operating...  Read More...
Sustainability: The changing climate of risk
March 30, 2011  |  Views: 1560 |  Comments: 0 
Sustainability: The changing climate of risk
This white paper is intended to be a catalyst not only for discussion around the risk issues raised by a changing climate, but also to serve as a guide to executives on how they ca...  Read More...
Page 1 of 2First   Previous   [1]  2  Next   Last   
Change selection(s) to sort. Sort by:
Benchmarking services
Views: 1228 |  Comments: 0  | Article Rating
Benchmarking services
The Benchmarking Portal's rapidly growing database contains information on nearly 90,000 policies covering $US50 billion in premium placements, $US4 trillion in limits, and $US15.5...  Read More...
Bowring Marsh: Global Casualty
Views: 790 |  Comments: 0  | Article Rating
Bowring Marsh: Global Casualty
Bowring Marsh’s global Casualty team comprises more than 60 dedicated brokers located in Bermuda, Dublin, Hong Kong, London, Miami, São Paulo, Singapore, Tokyo and Zurich. Our glob...  Read More...
Brand and reputation risk
Views: 1051 |  Comments: 0  | Article Rating
Brand and reputation risk
Companies can damage their brand image and reputation in numerous ways: poor service, a drop in product quality, environmental harm and unfair treatment of staff are some of the mo...  Read More...
Business interruption insurance
Views: 1023 |  Comments: 0  | Article Rating
Business interruption insurance
Losses from Business Interruption (BI) are often far greater than other losses such as property damage.   Read More...
CS STARS
Views: 1006 |  Comments: 0  | Article Rating
CS STARS
CS STARS LLC, a business unit of Marsh, serves the technology needs of risk management professionals, as well as insurance carriers and third-party administrators — delivering inte...  Read More...
Product recall
Views: 855 |  Comments: 0  | Article Rating
Product recall
Each year, government agencies announce thousands of product recalls involving such diverse products as toys, electrical and electronic products, fire sprinklers, household applian...  Read More...
Change selection(s) to sort. Sort by:
Regional Overview — EMEA
July 21, 2011  |  Views: 1107 |  Comments: 0  | Article Rating
Regional Overview — EMEA
Over the first half of 2011, the insurance market faced natural catastrophes, threats of political instability and legislative changes. This has led to the prospect of significant ...  Read More...
Change selection(s) to sort. Sort by:
Department of Justice 'pharma initiative' heightens risk for pharmaceutical companies
August 04, 2010  |  Views: 1004 |  Comments: 0  | Article Rating
Department of Justice 'pharma initiative' heightens risk for pharmaceutical companies
The U.S. Department of Justice (DOJ) recently announced that it would aggressively prosecute drug and medical device companies for bribes paid to third-party investigators to influ...  Read More...
Companies face complex clinical trials regulatory environment in EU
August 02, 2010  |  Views: 818 |  Comments: 0  | Article Rating
Companies face complex clinical trials regulatory environment in EU
Life sciences firms in the European Union (EU) must comply with a challenging regulatory environment when conducting clinical trials (CTs), due to the regional differences in CT re...  Read More...
Pharmaceutical companies may be held liable for chemicals found in water supplies
June 17, 2010  |  Views: 924 |  Comments: 0  | Article Rating
Pharmaceutical companies may be held liable for chemicals found in water supplies
Pharmaceutical companies face an evolving risk of pharmaceuticals and personal care products (PPCP) in ground and drinking water supplies.   Read More...
Marsh CEO: Insurance industry needs differentiation, innovation
May 25, 2010  |  Views: 1653 |  Comments: 0  | Article Rating
Marsh CEO: Insurance industry needs differentiation, innovation
Marsh chairman and CEO Dan Glaser described the multiple challenges facing the risk management and insurance communities in a recent speech to insurance industry leaders at InsideS...  Read More...
Change selection(s) to sort. Sort by:
February 07, 2011  |  Views: 1486
Soft insurance market conditions set to continue into 2011: Marsh
Soft commercial insurance market conditions persisted throughout Europe, the Middle East and Africa (EMEA) in 2010 and are set to continue into 2011, according to a comprehensive r...  Read More...
November 23, 2009  |  Views: 1045
Customer-related and credit risks top agendas for Europe’s leading firms
New research by Marsh, the world’s leading insurance broker and risk adviser, reveals that senior executives in Europe’s leading organisations are most concerned about customer-rel...  Read More...
August 26, 2009  |  Views: 1025
Excess capacity and competition stifling insurance rate increases in Europe, the Middle East and Africa
Insurance premium rate reductions slowed for property and casualty business across Europe, the Middle East and Africa in the first half of 2009, according to figures released today...  Read More...
July 17, 2009  |  Views: 691
Cash flow risk poses greatest threat to European life science firms: Marsh survey
Over three-quarters of senior executives at Europe’s leading life science companies have identified cash flow as the biggest threat to their long-term success, according to new res...  Read More...

Contacts
Christopher Bryce

London, United Kingdom
20 7357 3106
christopher.bryce@marsh.com
   
Request Information